Showing results (61-70 of 148) with videos related to

Sort By:
Pageof 15
The American Journal of Cardiology|January 28, 2010
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial)John C LaRosa, Prakash C Deedwania, James Shepherd, et al.
The American Journal of Cardiology|March 5, 2016
Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study)James Shepherd, Andrei Breazna, Prakash C Deedwania, et al.
Heart (British Cardiac Society)|February 18, 2011
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivationJennifer Logue, Heather M Murray, Paul Welsh, et al.
The American Journal of Cardiology|October 7, 2004
Safety of rosuvastatinJames Shepherd, Donald B Hunninghake, Evan A Stein, et al.
European Heart Journal|April 17, 2010
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-upDavid Preiss, Paul Welsh, Heather M Murray, et al.
Current Medical Research and Opinion|October 7, 2004
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapyJames Shepherd, Chris Packard, Thomas W Littlejohn, et al.
The American Journal of Cardiology|November 6, 2013
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart diseaseAntonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, et al.
Atherosclerosis|June 23, 2017
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURNRishi Puri, Christie M Ballantyne, Ron C Hoogeveen, et al.
Atherosclerosis|September 25, 2007
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS StudyHeide Stirnadel, Xiwu Lin, Hua Ling, et al.
Atherosclerosis|July 18, 2002
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance ratesLorne F Forster, Grace Stewart, Dorothy Bedford, et al.
Pageof 15